SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Star Therapeutics, a biotechnology company focused on the discovery and development of life-changing therapies for diseases with significant unmet need, today announced a $200 million private financing. The financing follows the July 2026 acquisition of Star subsidiary Vega Therapeutics and was co-led by OrbiMed and Janus Henderson Investors, with participation from Agent Capital, Catalio Capital Management, Cormorant Asset Management, New Leaf Vent